176 related articles for article (PubMed ID: 12786834)
21. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy.
Lever R; Hadley K; Downey D; Mackie R
Br J Dermatol; 1988 Aug; 119(2):189-98. PubMed ID: 3139019
[TBL] [Abstract][Full Text] [Related]
22. Interventions to reduce Staphylococcus aureus in the management of atopic eczema.
Birnie AJ; Bath-Hextall FJ; Ravenscroft JC; Williams HC
Cochrane Database Syst Rev; 2008 Jul; (3):CD003871. PubMed ID: 18646096
[TBL] [Abstract][Full Text] [Related]
23. Skin colonization of Staphylococcus aureus in atopic dermatitis patients seen at the National Skin Centre, Singapore.
Goh CL; Wong JS; Giam YC
Int J Dermatol; 1997 Sep; 36(9):653-7. PubMed ID: 9352404
[TBL] [Abstract][Full Text] [Related]
24. Staphylococcus aureus and topical fusidic acid use: results of a clinical audit on antimicrobial resistance.
Heng YK; Tan KT; Sen P; Chow A; Leo YS; Lye DC; Chan RK
Int J Dermatol; 2013 Jul; 52(7):876-81. PubMed ID: 23432159
[TBL] [Abstract][Full Text] [Related]
25. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis.
Nilsson EJ; Henning CG; Magnusson J
J Am Acad Dermatol; 1992 Jul; 27(1):29-34. PubMed ID: 1619073
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility of Staphylococcus aureus in children with atopic dermatitis.
Tang CS; Wang CC; Huang CF; Chen SJ; Tseng MH; Lo WT
Pediatr Int; 2011 Jun; 53(3):363-7. PubMed ID: 20723106
[TBL] [Abstract][Full Text] [Related]
27. Emergence of a Staphylococcus aureus Clone Resistant to Mupirocin and Fusidic Acid Carrying Exotoxin Genes and Causing Mainly Skin Infections.
Doudoulakakis A; Spiliopoulou I; Spyridis N; Giormezis N; Kopsidas J; Militsopoulou M; Lebessi E; Tsolia M
J Clin Microbiol; 2017 Aug; 55(8):2529-2537. PubMed ID: 28592549
[TBL] [Abstract][Full Text] [Related]
28. High levels of fusidic acid-resistant Staphylococcus aureus despite restrictions on antibiotic use.
Mitra A; Mohanraj M; Shah M
Clin Exp Dermatol; 2009 Mar; 34(2):136-9. PubMed ID: 18828847
[TBL] [Abstract][Full Text] [Related]
29. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK.
Ravenscroft JC; Layton A; Barnham M
Clin Exp Dermatol; 2000 Jun; 25(4):327-30. PubMed ID: 10971497
[TBL] [Abstract][Full Text] [Related]
30. Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents.
Watanakunakorn C; Axelson C; Bota B; Stahl C
Am J Infect Control; 1995 Oct; 23(5):306-9. PubMed ID: 8585642
[TBL] [Abstract][Full Text] [Related]
31. The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from patients with atopic dermatitis.
Harkins CP; McAleer MA; Bennett D; McHugh M; Fleury OM; Pettigrew KA; Oravcová K; Parkhill J; Proby CM; Dawe RS; Geoghegan JA; Irvine AD; Holden MTG
Br J Dermatol; 2018 Oct; 179(4):951-958. PubMed ID: 29729180
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections and its implications in various clinical conditions in Korea.
Baek YS; Jeon J; Ahn JW; Song HJ
Int J Dermatol; 2016 Apr; 55(4):e191-7. PubMed ID: 26892888
[TBL] [Abstract][Full Text] [Related]
33. Interventions to reduce Staphylococcus aureus in the management of eczema.
George SM; Karanovic S; Harrison DA; Rani A; Birnie AJ; Bath-Hextall FJ; Ravenscroft JC; Williams HC
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684694
[TBL] [Abstract][Full Text] [Related]
34. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study.
Mason BW; Howard AJ
Int J Antimicrob Agents; 2004 Mar; 23(3):300-3. PubMed ID: 15164973
[TBL] [Abstract][Full Text] [Related]
35. Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area.
El-Zimaity D; Kearns AM; Dawson SJ; Price S; Harrison GA
J Antimicrob Chemother; 2004 Aug; 54(2):441-6. PubMed ID: 15269197
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of combination ointment "fluticasone propionate 0.005% plus mupirocin 2.0%" for the treatment of atopic dermatitis with clinical suspicion of secondary bacterial infection: an open label uncontrolled study.
Khobragade KJ
Indian J Dermatol Venereol Leprol; 2005; 71(2):91-5. PubMed ID: 16394380
[TBL] [Abstract][Full Text] [Related]
37. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin.
Fawley WN; Parnell P; Hall J; Wilcox MH
J Hosp Infect; 2006 Mar; 62(3):327-32. PubMed ID: 16377029
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome.
Talpur R; Bassett R; Duvic M
Br J Dermatol; 2008 Jul; 159(1):105-12. PubMed ID: 18489588
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study.
Kircik LH
J Drugs Dermatol; 2012 Jul; 11(7):858-60. PubMed ID: 22777229
[TBL] [Abstract][Full Text] [Related]
40. Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The Netherlands.
Rijnders MI; Wolffs PF; Hopstaken RM; den Heyer M; Bruggeman CA; Stobberingh EE
J Antimicrob Chemother; 2012 May; 67(5):1176-80. PubMed ID: 22290345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
